Vendor Intelligence Report: Henan Sahe Peptide
Published 12 Nov 2026. 37-page investigative report on who is behind Henan Sahe Peptide: corporate records, ownership, affiliate networks, and the vendor's lab-testing record. The first 4 pages are free to read on this page.
Researched and published by Finnrick Analytics. Reports draw on corporate records, affiliate-network analysis, and Finnrick's own laboratory testing record; vendors can challenge findings through the formal objections process at finnrick.com/vendor-support/objections.
Executive summary
Across 99 Finnrick lab tests, Henan Sahe Peptide records 63 pass / 35 fail, an overall pass rate of 64%. The signal is not a blanket reject, but it is sharply product-specific. Tirzepatide is the strongest relative choice in the tested catalog, GHK-Cu is directionally acceptable with lot proof, Retatrutide has the deepest sample history but real failures, and MOTS-c is the clearest avoid. Ratings also compress under stricter grading, so the public score can overstate confidence for buyers seeking tighter fill and purity consistency.
The company record is less clean than the product names suggest. The report maps a Sahe/SH brand cluster that runs from a snippet-supported Zhengzhou trading-company anchor to 2025 Sahe and SH Peptide web launches, then to a 2026 Dubai retail layer under SH Labz. One former SH Peptide storefront is now expired parking, while the Dubai operator name is visible to readers but rendered through CSS in a way that frustrates basic text extraction. The same Dubai FZCO name also appears on an unrelated furniture storefront.
Factory-direct claims remain unverified, but the white-label evidence is more concrete: Janoshik-linked documents for downstream brands identify shpeptide.com as manufacturer, and SH batch families propagate across third-party pages. The report also separates buyer-useful signals from noise: SH Labz offers better payment recourse than the China-side WhatsApp route, while former Trustpilot-style social proof, vendor-hosted reviews, affiliate pages and parasite-SEO captures all require skepticism.
Inside the full report:
- Per-product pass/fail rates and methodology-divergence charts for all 11 tested products
- Corporate and brand map covering the Zhengzhou anchor, Sahe domains, SH Peptide expiry, SH Labz and SHCollectives
- COA crosswalk linking SH Labz, LookChem and Delix Labs records to shpeptide.com manufacturer fields
- Payment, logistics and genuine-channel verification guide for China-side versus Dubai purchase paths
- Reputation and promotion dossier covering Trustpilot-style claims, vendor-hosted reviews, affiliate pages and parasite-SEO captures
Risk assessment
- Product-specific quality risk — high: MOTS-c is 34.33% across 6 tests with 2 pass / 4 fail; TB-500, CJC-IPA, Tesamorelin and Cagrilintide are weak on three-test samples, while KLOW and Ipamorelin show zero passes in small samples.
- Ownership and channel-control opacity risk — high: UBO is unresolved; SHCOMMERCE TRADING - FZCO is operator-stated but not registry-verified, its name is CSS-injected on SH Labz, and the China-side anchor remains snippet-based.
- Copycat / brand-confusion risk — high: shpeptide.com is expired, sahepeptide.com is a thin mirror, shpeptides.com is parked/unrelated, and a Sahe-keyword WhatsApp funnel was found; no official-channels list or anti-counterfeit checker was found.
- Misleading or unverifiable reputation risk — high: The former shpeptide.com displayed unsupported Trustpilot-style 4.5 / 12,132-review social proof, while SH Labz’s 1,793-review claim is vendor-hosted and unauditable from the page.
- Factory-claim and batch-control verification risk — medium: Sahe claims factory-direct/OEM and automated production, but no manufacturing licence, facility audit, production address or named batch-release owner was found.
- Affiliate / SEO promotion risk — medium: SH Labz now has a 15% affiliate programme and disclosed affiliate content, while unrelated high-authority parasite-SEO pages promote Sahe/SH terms with attribution unresolved.
- Controlled-substance-adjacent promotion risk — medium: The Anabolex sales post offered peptides alongside anabolic steroids and raw powders, increasing seizure and payment-scrutiny exposure for buyers using those channels.